Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World StudyThomas B. Casale, Bradley E. Chipps, Allan T. Luskin et al.|The Journal of Allergy and Clinical Immunology In Practice|2018Cited by 277
Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthmaThomas B. Casale, Nicola A. Hanania, Bradley E. Chipps et al.|Allergy|2017Cited by 156
No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac DiseaseJoseph A. Murray, Richard A. Krause, K Ayub et al.|Gastroenterology|2016Cited by 137
Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERONicola A. Hanania, Thomas B. Casale, Bradley E. Chipps et al.|Journal of Allergy and Clinical Immunology|2018Cited by 70